GB201115937D0 - 18F-labelled compounds for use as positron emission imaging agents - Google Patents

18F-labelled compounds for use as positron emission imaging agents

Info

Publication number
GB201115937D0
GB201115937D0 GB201115937A GB201115937A GB201115937D0 GB 201115937 D0 GB201115937 D0 GB 201115937D0 GB 201115937 A GB201115937 A GB 201115937A GB 201115937 A GB201115937 A GB 201115937A GB 201115937 D0 GB201115937 D0 GB 201115937D0
Authority
GB
United Kingdom
Prior art keywords
positron emission
imaging
compounds
disease
imaging agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201115937A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Priority to GB201115937A priority Critical patent/GB201115937D0/en
Publication of GB201115937D0 publication Critical patent/GB201115937D0/en
Priority to PCT/GB2012/052206 priority patent/WO2013038153A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to the field of diagnostic methods. More specifically, the present invention pertains to certain 18F-labelled barbiturate compounds of the following formula (collectively referred to herein as "18F-fluorinated barbiturate compounds" and "18FBAR compounds") that bind to metals, for example, metals associated with protein aggregates, and as such are useful as imaging agents for positron emission imaging (e.g., positron emission tomography (PET) imaging) used in the diagnosis and monitoring of conditions involving these aggregates, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). These compounds also bind strongly to GABAA receptors and hence are also useful as imaging agents for positron emission tomography (PET) imaging used in the diagnosis, monitoring and study of diseases involving dis-regulation of these receptors, including epilepsy, schizophrenia, and mood disorders (e.g., anxiety).
GB201115937A 2011-09-14 2011-09-14 18F-labelled compounds for use as positron emission imaging agents Ceased GB201115937D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201115937A GB201115937D0 (en) 2011-09-14 2011-09-14 18F-labelled compounds for use as positron emission imaging agents
PCT/GB2012/052206 WO2013038153A1 (en) 2011-09-14 2012-09-07 18f-labelled barbiturate compounds for use as positron emission imaging agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201115937A GB201115937D0 (en) 2011-09-14 2011-09-14 18F-labelled compounds for use as positron emission imaging agents

Publications (1)

Publication Number Publication Date
GB201115937D0 true GB201115937D0 (en) 2011-10-26

Family

ID=44908608

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201115937A Ceased GB201115937D0 (en) 2011-09-14 2011-09-14 18F-labelled compounds for use as positron emission imaging agents

Country Status (2)

Country Link
GB (1) GB201115937D0 (en)
WO (1) WO2013038153A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
CN113201007A (en) * 2021-05-31 2021-08-03 四川大学华西医院 Fluorescent probe for detecting fluorine ions, application thereof and method for detecting fluorine ions in sample to be detected
CN114479101B (en) * 2022-01-22 2023-01-17 中北大学 Supramolecular gel composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1989A (en) 1841-02-20 Stump-extractor
GB1073299A (en) 1964-08-21 1967-06-21 Aspro Nicholas Ltd Improvements in or relating to the manufacture of barbituric acid derivatives
US4833148A (en) 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
CN1307708A (en) 1998-06-26 2001-08-08 智能卡德技术公司 Data system with support surfaces for reciprocating data head
CN1314994A (en) 1998-06-26 2001-09-26 医疗指示器公司 Liquid crystal thermometer
CA2471436C (en) 2002-01-30 2011-10-11 Taro Pharmaceutical Industries Ltd. Non-sedating barbituric acid derivatives
NI200300045A (en) 2002-04-26 2005-07-08 Pfizer Prod Inc INHIBITORS OF TRIARILOXIARILOXIPIRIMIDIN-2,4,6-METALOPROTEINASE TRION.
GB0223249D0 (en) 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents

Also Published As

Publication number Publication date
WO2013038153A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112014012822A8 (en) FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANTS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2
BR112015025140A2 (en) 2-phenylimidazo [1,2-a] pyrimidines as imaging agents
MY164579A (en) Safe and functional humanized antibodies
BR122019022071B8 (en) compound for inhibiting the aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases and in aggregated protein imaging deposits, use thereof, and kit
CO7131359A2 (en) Imaging agents to detect neurological dysfunction
NZ713762A (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PE20160159A1 (en) DIAZACARBAZOLE DERIVATIVES AS TAU LIGANDS FOR PET
IL231620A0 (en) Method for diagnosing alzheimer's disease (ad)
WO2014160871A3 (en) Methods and agents for treating alzheimer's disease
ZA201404500B (en) Methods for diagnosing alzheimer's disease
GB201112246D0 (en) Diagnosis of alzheimer's disease
BR112019000946A2 (en) compounds for imaging tau protein aggregates
ECSP11010850A (en) NEW SUITABLE COMPOUNDS AS COMPOUND PRECURSORS THAT ARE USEFUL TO OBTAIN IMAGES OF AMYLOOID DEPOSITS
EA201691831A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS
GB201115937D0 (en) 18F-labelled compounds for use as positron emission imaging agents
CO2020008834A2 (en) New method to prepare compound for imaging
CL2015001881A1 (en) Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition.
EA201691788A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS
EP2791676A4 (en) Methods for diagnosing alzheimer's disease
EA201300479A1 (en) CONNECTIONS FOR APPLICATION IN VISUALIZATION, DIAGNOSTICS AND / OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP2990801A4 (en) Diagnostic kit for diagnosing disorders or diseases related to abnormal protein aggregation or misfolding of protein using dissolution of protein aggregates
GB201105445D0 (en) Radiolabelled flumazenil derivatives
WO2013173746A3 (en) Fluorinated derivatives of 4-aminopyridine
FR2985899B1 (en) TREATMENT OF INTERVENTIONAL RADIOLOGY IMAGES BY ECG ANALYSIS
Dickerson et al. Imaging tau pathology in vivo in FTLD: initial experience with [18F] T807 PET

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)